OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 90.5% during the 4th quarter, HoldingsChannel.com reports. The fund owned 125,589 shares of the company’s stock after purchasing an additional 59,649 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in iTeos Therapeutics were worth $965,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Virtus ETF Advisers LLC increased its stake in iTeos Therapeutics by 58.2% during the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock valued at $69,000 after purchasing an additional 3,293 shares in the last quarter. Forefront Analytics LLC purchased a new stake in shares of iTeos Therapeutics during the fourth quarter valued at $85,000. Graham Capital Management L.P. purchased a new stake in shares of iTeos Therapeutics during the fourth quarter valued at $85,000. Clear Harbor Asset Management LLC acquired a new position in shares of iTeos Therapeutics in the 4th quarter valued at $96,000. Finally, SG Americas Securities LLC raised its stake in iTeos Therapeutics by 12.2% in the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock worth $106,000 after acquiring an additional 1,508 shares during the last quarter. 97.16% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ITOS has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price target on shares of iTeos Therapeutics in a research report on Thursday, March 6th. JPMorgan Chase & Co. downgraded iTeos Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $15.00 to $8.00 in a report on Tuesday. Wells Fargo & Company dropped their price objective on shares of iTeos Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a report on Tuesday, April 29th. Finally, Wedbush reissued an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a report on Wednesday, March 5th.

iTeos Therapeutics Trading Up 13.4%

iTeos Therapeutics stock opened at $7.85 on Wednesday. The firm has a market cap of $300.45 million, a PE ratio of -2.49 and a beta of 1.39. The stock’s 50 day simple moving average is $6.56 and its two-hundred day simple moving average is $7.43. iTeos Therapeutics, Inc. has a 12 month low of $4.80 and a 12 month high of $18.70.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.14. On average, equities research analysts forecast that iTeos Therapeutics, Inc. will post -3.49 EPS for the current year.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.